Entries by Michael Kuhrt

Mologen: Preparing for market launch

Starting in  May, Matthias Baumann will be new Chief Medical Officer of immunotherapy specialist Mologen AG. His primary goal will be preparing Mologen’s DNA cancer therapy lefitolimod for market launch.

Genmab: Pushing for growth

Ex-Novartis Senior VP Judith Klimovsky has joined Copenhagen-based Genmab as Executive Vice President and Chief Development Officer. The appointment is meant to pave the way for the antibody specialist to grow into a global biotech company. 

One Nucleus: Seasoned Director

One Nucleus, the Cambridge-based not-for-profit membership organisation for international life science and healthcare companies, announced the appointment of Linda Summerton as a Director. Summerton is Chief Executive of Immodulon and a Senior Partner with TranScrip Partners.

Medherant: Chair for the clinic

University of Warwick spin-out Medherant Ltd has appointed Ken Cunningham as its chair right in time for the company’s move into the clinical development of its novel transdermal drug delivery patch technology. Cunningham is already Chairman of Abzena as well as Non-Executive Director of Verona Pharma plc. 

Applied Photophysics: Risen through the ranks

Applied Photophysics, a provider of systems for the biophysical characterisation of biomolecules, has appointed Louise Madden as Chief Executive Officer. She joined Applied Photophysics in March 2014 as commercial director, before being promoted to chief operating officer in 2015.

Santhera: The doctor takes charge

Developer of treatments for neuromuscular and neuro-ophthalmological diseases Santhera Pharmaceuticals has hired Kristina Sjöblom Nygren as Chief Medical Officer and Head of Development.

Virovet: Veterinarian comes on board

Belgian ViroVet NV, which develops vaccines and antiviral drug for livestock, has named George Gunn as the newest member of its board of directors. Until early 2015, Gunn was CEO of Novartis Animal Health and a member of the global executive committee of Novartis. 

Making Brexit work for the life sciences sector

Like every sector of the UK economy, life sciences has been beset with uncertainty since the country voted to leave the European Union. Last week prime minister Theresa May finally gave us some clarity on her plans for Brexit, which will allow us to prepare for the future.

Will the Trump effect last?

The surprising election of Donald Trump as the next US President led to a spectacular comeback of biotech shares. The long-term prospects depend on Trump’s healthcare strategy and the (much-desired) return of generalist funds.